DCG-IV

Из Википедије, слободне енциклопедије
DCG-IV
DCGIV structure.png
IUPAC ime
(1R,2R)-3-[(1S)-1-amino-2-hidroksi-2-oksoetil]ciklopropan-1,2-dikarboksilna kiselina
Identifikatori
CAS broj 147782-19-2 ДаY
ATC kod none
PubChem CID 5310979
Hemijski podaci
Formula C7H9NO6
Molarna masa 203,149 g/mol
  (verify)

DCG-IV je lek koji se koristi u naučnim istraživanjima. On deluje kao agonist za grupu II metabotropnih glutamatnih receptora (mGluR2/3).[1] On ima potentne neuroprotektivne i antikonvulsantne efekte u životinjskim studijama.[2][3][4][5] On isto tako pokazuje antiparkinsonove efekte,[6][7] mada je poznato da usporava formiranje memorija.[8][9]

Reference[уреди]

  1. Ishida M, Saitoh T, Shimamoto K, Ohfune Y, Shinozaki H (1993). „A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the newborn rat isolated spinal cord”. British Journal of Pharmacology. 109 (4): 1169—77. PMC 2175774слободно за читање. PMID 8401927. 
  2. Bruno V, Copani A, Battaglia G, Raffaele R, Shinozaki H, Nicoletti F (1994). „Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death”. European Journal of Pharmacology. 256 (1): 109—12. doi:10.1016/0014-2999(94)90624-6. PMID 7517889. 
  3. Yoshioka H, Sugita M, Kinouchi H (2009). „Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia”. Neuroscience Letters. 461 (3): 266—70. doi:10.1016/j.neulet.2009.06.056. PMID 19549561. 
  4. Attwell PJ, Singh Kent N, Jane DE, Croucher MJ, Bradford HF (1998). „Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV)”. Brain Research. 805 (1-2): 138—43. doi:10.1016/S0006-8993(98)00698-2. PMID 9733953. 
  5. Fei Z, Zhang X, Bai HM, Jiang XF, Wang XL (2006). „Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury”. Journal of Clinical Neuroscience. 13 (10): 1023—7. doi:10.1016/j.jocn.2005.11.042. PMID 17113985. 
  6. Dawson L, Chadha A, Megalou M, Duty S (2000). „The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat”. British Journal of Pharmacology. 129 (3): 541—6. doi:10.1038/sj.bjp.0703105. PMC 1571875слободно за читање. PMID 10711353. 
  7. Venero JL, Santiago M, Tomás-Camardiel M, Matarredona ER, Cano J, Machado A (2002). „DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury”. Neuroscience. 113 (4): 857—69. doi:10.1016/S0306-4522(02)00232-4. PMID 12182892. 
  8. Huang LQ, Rowan MJ, Anwyl R (1997). „mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD induction, in the dentate gyrus in vitro”. Neuroreport. 8 (3): 687—93. doi:10.1097/00001756-199702100-00022. PMID 9106748. 
  9. Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (2004). „Inhibitory effects of group II mGluR-related drugs on memory performance in mice”. Physiology & Behavior. 80 (5): 747—58. doi:10.1016/j.physbeh.2003.12.010. PMID 14984810. 

Spoljašnje veze[уреди]